Ab&B Bio Tech Co Ltd JS

Ab&B Bio Tech Co Ltd JS P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Ab&B Bio Tech Co Ltd JS (2627.HK) as of Oct 22, 2026 is -35.64. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -23.86 — a change of 49.41% (lower).

P/FCF

-35.64

YoY

49.41%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Ab&B Bio Tech Co Ltd JS is 2024 -35.64 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Ab&B Bio Tech Co Ltd JS was 2023 -23.86 . It decreases by 49.41% lower compared to the previous year.

The Ab&B Bio Tech Co Ltd JS P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2023
-23.86 CNY
Jan 1, 2024
-35.64 CNY
The Ab&B Bio Tech Co Ltd JS P/FCF history
YEARP/FCFYoY
-35.64+49.41%
-23.86—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ab&B Bio Tech Co Ltd JS Stock analysis

What does Ab&B Bio Tech Co Ltd JS do? Ab&B Bio Tech Co Ltd JS generates revenue through the research, development, manufacturing, and commercialization of vaccines. The company's core products include the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, alongside 11 other vaccine candidates. It primarily serves the domestic market in China, focusing on vaccine solutions for public health needs. The company's business model centers on bringing its vaccine pipeline to market through domestic sales and commercialization efforts. The firm operates within the biotechnology industry, specifically targeting vaccine development and production. Its product portfolio consists of two core vaccines and 11 additional candidates, all aimed at addressing infectious disease prevention. Ab&B Bio Tech Co Ltd JS leverages its domestic market presence to sell these products, with no mention of international sales or partnerships in the business description. The company's revenue streams derive from the commercialization of its vaccine pipeline, including the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate. It focuses on the Chinese domestic market for product distribution and sales, with no indication of export activities or foreign market engagement. Ab&B Bio Tech Co Ltd JS's business model emphasizes in-country development and sales of vaccines to meet local healthcare demands. Ab&B Bio Tech Co Ltd JS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ab&B Bio Tech Co Ltd JS stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Ab&B Bio Tech Co Ltd JS is -35.64 in 2024.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Ab&B Bio Tech Co Ltd JS changed from -23.86 to -35.64, representing a 49.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Ab&B Bio Tech Co Ltd JS since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Ab&B Bio Tech Co Ltd JS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Ab&B Bio Tech Co Ltd JS

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Ab&B Bio Tech Co Ltd JS